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Abstract 
Background 
In veterinary medicine and animal husbandry, there is a need for tools allowing the early 
warning of diseases. Preferably, tests should be available that warn farmers and veterinarians 
during the incubation periods of disease and before the onset of clinical signs. The objective 
of this study was to explore the potential of serum protein profiles as an early biomarker for 
infectious disease status. Serum samples were obtained from an experimental pig model for 
porcine circovirus-associated disease (PCVAD), consisting of Porcine Circovirus type 2 
(PCV2) infection in combination with either Porcine Parvovirus (PPV) or Porcine 
Reproductive and Respiratory Syndrome virus (PRRSV). Sera were collected before and after 
onset of clinical signs at day 0, 5 and 19 post infection. Serum protein profiles were evaluated 
against sera from non-infected control animals. 
Results 
Protein profiles were generated by SELDI-TOF mass spectrometry in combination with the 
Proteominer™ technology to enrich for low-abundance proteins. Based on these protein 
profiles, the experimentally infected pigs could be classified according to their infectious 
disease status. Before the onset of clinical signs 88% of the infected animals could be 
classified correctly, after the onset of clinical sigs 93%. The sensitivity of the classification 
appeared to be high. The protein profiles could distinguish between separate infection 
models, although specificity was moderate to low. Classification of PCV2/PRRSV infected 
animals was superior compared to PCV2/PPV infected animals. Limiting the number of 
proteins in the profiles (ranging from 568 to 10) had only minor effects on the classification 
performance. 
Conclusions 
This study shows that serum protein profiles have potential for detection and identification of 
viral infections in pigs before clinical signs of the disease become visible. 
Background 
In present livestock husbandry with increasing requirements for higher health and welfare 
issues but also tight economical margins, there is a need for tools allowing the early warning 
for disease. Ideally, easy to perform tools should be available that warn farmers and 
veterinarians that animals are infected, preferably before the onset of clinical signs. Regular 
use of such tools may diminish growth retardations and production losses. However, tests for 
early diagnosis can only be developed when animal-associated “biomarkers” exist that differ 
between uninfected healthy animals and infected, but not yet diseased, animals. The search 
for such biomarkers can be performed by two different approaches, either focusing on 
differences in predefined “candidate” markers, or by comparative fingerprint analysis of “all” 
components present in a biological sample. 
In human medicine extensive research has been performed aiming at the discovery of early 
biomarkers for different kinds of disease, including cancer. Early diagnosis is important 
because of increased treatment options and better prognosis when treatments are initiated at 
an earlier stage [1–3]. In such settings, involving alteration of several pathways and 
processes, it has been suggested that multiple marker assays lead to an increase in clinical 
sensitivity and specificity relative to single-marker assays [4]. Also for the early detection of 
infections in veterinary medicine it has been shown that a combination of protein biomarkers 
increases the performance, i.e. for transmissible spongiform encephalopathies (TSEs), 
paratuberculosis, Dichelobacternodosus and Fasciola hepatica [5–9]. 
The discovery of potential biomarkers for a number of human and animal diseases has been 
facilitated by proteomic analysis, some of which have already been commercialized [10]. 
Comparative proteomic analyses can be performed relatively easily using surface enhanced 
laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) [11]. SELDI-
TOF-MS technology includes the use of protein chip arrays that specifically bind intact 
proteins present in biological samples, such as body fluids or tissue extracts. Arrays may vary 
in their surface chemistry, for instance they may have hydrophobic or hydrophilic properties, 
thereby selectively binding proteins. Protein components are solely identified by their 
specific molecular weights. By comparing SELDI-TOF-MS profiles, protein components that 
differ in abundance between (groups of) samples can be recognized. 
SELDI-TOF-MS generates a profile of peaks representing the relative abundance of each 
protein component retained on the chip and has a high specificity in distinguishing (groups 
of) samples. This is especially true when used in combination with a technology to enrich 
low-abundant proteins, i.e. the Proteominer™ technology, which is based on affinity 
chromatography using a solid phase combinatorial peptide ligand library. The latter leads to a 
reduction of the dynamic range of plasma protein concentrations and an improved access to 
low abundant proteins. The combination of these technologies provides protein profiles 
representing the relative concentrations of a large number of high- and low-abundant proteins 
in a biological sample [12,13]. In addition, this technology can be used at a medium 
throughput scale. 
To assess the potential of serum protein profiles as a diagnostic marker for viral infectious 
diseases in pigs, we used an experimental animal model for porcine circovirus-associated 
disease (PCVD), an important swine disease mostly known in the manifestation of 
postweaningmultisystemic wasting syndrome (PMWS). It is, at present, one of the most 
economically important diseases in swine industry. Although Porcine Circovirus type 2 
(PCV2) is regarded as the primary causative agent, PCVD is considered a multifactorial 
disease. PCV2 pathogenesis appears to be related to the immune-modulatory effects of the 
virus while other micro-organisms contribute to the clinical signs associated with PCVD. 
Both porcine parvovirus (PPV) and porcine reproductive and respiratory syndrome virus 
(PRRSV) have been shown to be associated as co-factors. Experimental co-infections of PPV 
or PRRSV with PCV2 have fully reproduced PCVAD. These data have been supported by 
field data in which these viruses have been isolated in association with PMWS [14]. 
The objective of this study was to explore the potential of serum protein profiles consisting of 
both high- and low-abundant proteins, as measured by SELDI-TOF-MS, for the diagnosis of 
early infectious disease status in pigs. To this end the serum protein profiles, obtained from 
experimentally infected PCV2/PPV, PCV2/PRRSV, and control animals were used to 
investigate the classification accuracy for different comparisons, i.e. infected versus non-
infected, PCV2/PPV versus control, PCV2/PRRSV versus control, and the three-way 
classification PCV2/PPV, PCV2/PRRSV, and control. In addition, we investigated the 
classification performance of subsets of protein profiles that varied in the number of used 
protein components. 
Results 
Clinical signs and pathology 
During the course of the experiment, all pigs infected with PCV2 in combination with either 
PPV or PRRSV developed clinical disease signs with a varying degree of severity. No 
systemic disease signs were observed in the control group with the exception of a temporary 
lameness in one pig and paleness in two pigs. Three pigs in the PCV2/PRRSV infected group 
and one pig from the PCV2/PPV infected group were euthanized for humane reasons at 25 
and 26 days post infection. Two pigs died directly after blood sampling, supposedly not 
related to the experimental infection; one from the control group (at 18 days post infection) 
and another pig from the PCV2/PRRSV group (at 12 days post infection). 
Pigs in both the PCV2/PRRSV and the PCV2/PPV infected groups showed signs of wasting 
with a significant difference in weekly body weight gain compared to the control group. This 
was consistently seen starting at one week post infection (p < 0.001 and p < 0.05, 
respectively). Body weight gain was significantly lower in the PCV2/PRRSV infected group 
compared to the PCV2/PPV infected group in the first week post infection. In the second 
week post infection, weight gain was similar in both infected groups. Data are shown in 
Figure 1A. 
Figure 1 Body weight gain (A), Body temperatures (B) and clinical scores (C) in 
experimentally infected groups. Course of the body weight gain (Figure 1A), body 
temperature (Figure 1B) and clinical scores (Figure 1C) were recorded in experimental 
groups of three weeks old, colostrum-deprived piglets inoculated with either a combination of 
PCV2 and PRRSV (PCV2/PRRSV), PCV2 and PPV (PCV2/PPV), or phosphate buffered 
saline (controls). For each experimental group consisting of eight (PCV2/PPV) or nine 
animals (PCV2/PRRSV, controls) data were collected for a period of 26 days post 
inoculation. Rectal temperatures were measured twice daily and clinical scores were 
determined based on a collection of predefined clinical symptoms ranging from no disease 
(0) to severe disease (3). Arrows (↑) indicate time of sampling for SELDI-TOF protein 
profiling. 
Mean rectal temperature in pigs in the PCV2/PRRSV infected group increased to febrile 
temperatures, i.e. rectal temperatures ≥40.0°C from two days post infection on for seven days 
and again elevated mean body temperatures were seen at 14 days post infection and for a 
period of five days between 18 and 23 days post infection (Figure 1B). In the PCV2/PPV 
infected group febrile body temperatures were observed incidentally at seven days post 
infection and at 13 days post infection. 
Clinical signs started to appear between day six and seven in all pigs from the PCV2/PRRSV 
infected group and also in a number of pigs from the PCV2/PPV infected group. In the 
PCV2/PRRSV group the mean clinical score, based on the occurrence and severity of clinical 
symptoms, reached 2.5 (moderate to severe disease) of a maximum score of 3. In this group 
severe disease signs started to develop from seven days post infection on (Figure 1C). In the 
PCV2/PPV infected group the manifestation of disease symptoms occurred slightly later and 
the mean clinical score was generally lower in this group. Clinical signs as severe depression 
were observed in more than 80% of all pigs from the PCV2/PRRSV group compared to 10% 
in the PCV2/PPV group. Whereas respiratory distress was recorded in all infected pigs, 75% 
from the PRRSV co-infected group showed signs of pneumonia and only about 20% of the 
PPV co-infected group (Figure 2). A palpable increase of the size of the inguinal lymph 
nodes was found in all PCV2/PRRSV infected pigs from 12 days post infection on and in 
three pigs from the PCV2/PPV infected group from 12, 19 or 21 days post infection on. 
Figure 2 Clinical symptoms in experimentally infected groups. The percentage of animals 
in three weeks old, colostrum-deprived piglets showing diverse signs of disease. 
Observations were made twice daily during a time frame of 26 days post inoculation with 
either a combination of PCV2 and PRRSV (PCV2/PRRSV), PCV2 and PPV (PCV2/PPV) or 
phosphate buffered saline (controls) 
At necropsy, typically for PMWS, inguinal lymph nodes and also other lymph nodes were 
enlarged in all infected pigs and the mean weights of the inguinal lymph nodes in both 
infected groups were higher than in the control group (PCV2/PRRSV vs. control, p <0.03; 
PCV2/PPV versus control, p <0.08). In the PCV2/PRRSV infected group two of nine pigs 
had a macroscopically identifiable pneumonia, although a moderate to severe interstitial 
pneumonia was found in eight of nine pigs based on histology. In the PCV2/PPV infected 
group macroscopic changes were restricted to increased size of the inguinal lymph node and 
kidney, liver or lung changes in a few pigs. Histologically, most striking was a slight to 
moderate hepatitis in seven of eight pigs. In five of 17 PCV2 infected pigs lymph node 
depletion was observed, in others a hyperplasia was more prominent. 
After termination of the experiment, tissue samples were tested for the presence of PRRSV 
and PCV2 nucleic acid detection by PCR. All infected animals showed strong positive results 
for PCV2 in lymph nodes, lung and spleen. Although in control animals no PCV2 nucleic 
acid was detected in pharyngeal swabs throughout the study, low levels of PCV2 nucleic acid 
were found in single or several tissue specimens of six control animals. PRRSV nucleic acid 
was detected in lungs of all PCV2/PRRSV infected animals but not of the other groups. No 
PCR testing has been performed for PPV. 
Acute phase proteins 
Results of acute phase proteins levels are summarized in Figure 3. At day five p.i. levels of 
acute phase proteins did not differ significantly compared to levels in sera collected prior to 
inoculation, except for pig major protein (PigMAP,p = 0.004) and albumin (p = 0.01) in the 
control group and PigMAP in the PCV2/PPV infected group (p = 0.035). More significant 
differences were observed at day 19 p.i. compared to levels at day zero for three acute phase 
proteins; haptoglobin (Hp) in the PCV2/PRRSV group (p < 0.001), PigMAP in PCV2/PPV 
(p = 0.023) and PCV2/PRRSV infected animals (p = 0.021), and albumin in PCV2/PPV 
(p = 0.002), PCV2/PRRSV infected animals (p = 0.003), as well as in the PBS treated control 
group (p = <0.001). 
Figure 3 Acute phase protein levels in experimentally infected groups. Mean levels of C-
reactive protein (CRP), serum amyloid A(SAA), haptoglobin (Hp), pig major protein 
(PigMAP), α-Lipoprotein (ApoA1), and albumin were determined in three weeks old, 
colostrum-deprived piglets inoculated with either a combination of PCV2 and PRRSV 
(PCV2/PRRSV), PCV2 and PPV (PCV2/PPV), or phosphate buffered saline (controls). 
Some statistically significant differences were observed comparing different experimental 
groups. At day zero, PigMAP levels in animals from the PCV2/PRRSV group (p = 0.013) and 
α-Lipoprotein (ApoA1) levels in the PCV2/PPV group (p < 0.001) were significantly different 
compared to the control group. At day five p.i., only ApoA1 (control group versus 
PCV2/PPV group, p = 0.004), and at day 19 only albumin (control group versus 
PCV2/PRRSV group, p = 0.032) were discriminative. 
SELDI-TOF proteomics 
Serum protein profiles were obtained on day zero as well as on day five post infection, before 
clinical symptoms became apparent. A third set of protein profiles was obtained at day 19 
post infection, when all animals from both experimental infections showed clear signs of 
disease. Using the Protein chip Data Manager software a total of 586 protein peaks were 
identified and subjected to further statistical analysis. It should be noted that these 586 
protein peaks may represent a lower number of proteins, as a certain overlap may be present 
among the results obtained with the three types of arrays that have been used. 
Protein profiles of serum obtained from all animals prior to infection (day 0) were tested for 
differences. No statistical significant differences could be observed between animal groups, 
indicating that in this respect, the three groups of animals were very similar at the time of 
infection. 
Overview of comparisons 
We performed multiple analyses, comparing the three experimental groups: animals 
inoculated with (i) PCV2 and PPV (PCV2/PPV); (ii) PCV2 and PRRSV (PCV2/PRRSV); 
and (iii) PBS (controls), at three time points. An overview of these analyses is given in 
Table 1. The comparisons can be categorized as follows: (1) infected animals (PCV2/PPV 
together with PCV2/PRRSV) versus non-infected control animals, (2) PCV2/PPV infected 
animals versus control animals or PCV2/PRRSV infected animals versus control animals, (3) 
PCV2/PPV, PCV2/PRRSV, and control animals as three distinct groups to explore the 
discriminatory power of serum protein profiles to distinguish the different infection models. 
Table 1 Overview of the statistical analyses (A-H) with the accompanying data sets that 
were used 
 Analysis   Day 5 p.i.   Day 19 p.i.  
2/3way comparison Day p.i. Control PCV2/ 
PPV 
PCV2/ 
PRRSV 
Control PCV2/ 
PPV 
PCV2/ 
PRRSV 
2-way Infected (A2) versus 
non-infected (A1) 
5, 19 A1a A2 A2 A1 A2 A2 
 PCV2/PPV versus 
control 
5 B1 B2     
 PCV2/PRRSV 
versus control 
5 C1  C2    
 PCV2/PPV versus 
control 
19    D1 D2  
 PCV2/PRRSV 
versus control 
19    E1  E2 
 PCV2/PPV versus 
control 
5, 19 F1 F2  F1 F2  
 PCV2/PRRSV versus control 5, 19 G1  G2 G1  G2 
3-way PCV2/PPV, 
PCV2/PRRSV, 
control 
5, 19 H1 H2 H3 H1 H2 H3 
a
 Serum protein profiles of animals in groups with the same code have been clustered for 
statistical analysis. 
Different comparisons (A-H) were carried out, including serum protein profiles of animals 
from different infection groups and/or time points after infection. SELDI-TOF-MS profiles 
were obtained from three week old piglets that were experimentally infected with either a 
combination of PCV2 and PRRSV (PCV2/PRRSV), PCV2 and PPV (PCV2/PPV), or 
phosphate buffered saline (controls). Statistical analyses were based on data from day five 
post infection (p.i.), day 19 p.i., or data from both days combined as indicated in the table. 
For each comparison the number of significantly different protein peaks in their profiles was 
determined as well as the classification accuracy. Additionally we tested whether reducing 
the number of protein peaks in a profile affected the accuracy of classification. Next to whole 
protein profiles consisting of 586 protein peaks, we also tested profiles with 500, 200, 100, 
50, 20, and 10 protein components. For this, proteins were ranked by significance and those 
with highest significance were selected. 
Number of significant different protein peaks 
For each comparison the number of significantly different protein peaks is shown in Table 2. 
Based on a maximum p-value of 0.01, the number of differentially expressed protein 
components ranged from 15 (PCV2/PPV versus control) to 59 (PCV2/PRRSV versus 
control). For a number of comparisons, molecular masses of the most significant differently 
expressed protein components are summarized in Table 3. 
Table 2 Overview of the number of significant differentially expressed protein 
components in different analyses 
  Number of significant proteins 
Analysis
a
 Day p.i. p < 0.01 FDR < 0.05 
Healthy versus  
diseased 
5, 19 49 13 
PCV2/PPV versus  
control 
5 26 1 
PCV2/PRRSV versus  
control 
5 36 1 
PCV2/PPV versus  
control 
19 15 - 
PCV2/PRRSV versus  
control 
19 17 - 
PCV2/PPV versus  
control 
5, 19 19 - 
PCV2/PRRSV versus  
control 
5, 19 59 43 
PCV2/PPV,  
PCV2/PRRSV, control 
5, 19 45 12 
a: See Table 1 for description of analysis. 
SELDI-TOF-MS protein profiles were generated from three week old piglets experimentally 
infected with either a combination of PCV2 and PRRSV (PCV2/PRRSV), PCV2 and PPV 
(PCV2/PPV), or phosphate buffered saline (controls). The number of significantly 
differentially expressed protein components with p < 0.01 or with False Discovery Rate 
(FDR) <0.05 for different analyses are indicated. 
 
Table 3 Most significantly differentially expressed protein components as characterized 
by mass:charge (m/z) value 
Analysis 
Infected vs controls PCV2/PPV vs 
control 
PCV2/PRRSV vs 
control 
PCV2/PPV,  
PCV2/PRRSV,and  
control 
m/z q-value m/z q-value m/z q-value m/z q-value 
5540 0.025 54287 0.055 5540 0.010 5540 0.034 
8720 0.032 10602 0.158 8720 0.013 147239 0.034 
54287 0.032 8565 0.209 147239 0.014 8720 0.034 
8565z 0.032 80028 0.283 17175 0.019 8720 0.034 
19966 0.034 8720 0.283 34135 0.019 34135 0.034 
14540 0.034 187711 0.283 19966 0.019 54287 0.037 
10436 0.037 2357 0.283 17171 0.019 64263 0.037 
11021 0.037 10516 0.283 10436 0.019 187711 0.037 
10726 0.037 10805 0.283 11021 0.019 5542 0.037 
2357 0.042 27621 0.283 5542 0.019 8193 0.037 
The ten most significantly differently expressed protein components for four analyses as 
characterized by mass:charge (m/z) value with their q-value (in Daltons) are summarized. 
SELDI-TOF-MS Protein profiles were generated from three week old piglets experimentally 
infected with either a combination of PCV2 and PRRSV (PCV2/PRRSV), PCV2 and PPV 
(PCV2/PPV), or phosphate buffered saline (controls). The figures are based on SELDI-TOF-
MS data from day five and 19 post infection combined. The overlap in protein components 
within different comparative analyses is due to the use of different SELDI-TOF-MS protein 
chip arrays. 
As expected, based on the False Discovery Rate (FDR), which may be more appropriate than 
p-values as it accounts for multiple testing, the amount of differentially expressed protein 
components was reduced. In a number of analyses, none of the protein components showed a 
significantly different expression based on an FDR <0.05. In general, more protein 
components were differentially expressed comparing PCV2/PRRSV infected animals versus 
non-infected control animals as opposed to PCV2/PPV infected versus control animals as 
shown in Table 2. Combining data of day five and day 19 post infection (p.i.) increased the 
number of significantly differentially expressed protein components. 
Two-group classification 
Infected animals versus non-infected animals 
In this analysis, PCV2/PPV along with PCV2/PRRSV infected animals were marked as 
infected, whereas control animals at day five and day 19 are regarded as non-infected 
(Table 1). Classification results are summarized in Table 4. 
Table 4 The number of animals correctly classified as either infected or non-infected 
 Day 5 p.i.  Day 19 p.i.  
number of proteins 
components 
 
non-infected 
 
infected 
 
non-infected 
 
infected 
10 4 (9) 10 (16) 1 (7) 14 (15) 
20 6 12 3 14 
50 7 14 3 14 
100 7 12 4 15 
200 6 13 4 14 
500 6 14 3 14 
586 6 14 4 14 
The number of correctly classified animals (infected versus non-infected) at day five and day 
19 post infection using increasing numbers of SELDI-TOF-MS protein components. Serum 
protein profiles were generated from three week old piglets experimentally infected with 
either a combination of PCV2 and PRRSV (PCV2/PRRSV), PCV2 and PPV (PCV2/PPV), or 
phosphate buffered saline (controls). In the top row, for each experimental group the total 
number of animals included in the analysis is specified between brackets. 
At day 19 post infection, both PCV2/PPV and PCV2/PRRSV infected animals displayed 
evident signs of illness with 14 of 15 (Sensitivity (Se) = 93.3%; specificity (Sp) = 57.1%) 
infected animals having significantly different serum protein profiles compared to non-
infected animals. Moreover at day five, before any disease symptoms were apparent, 14 of 16 
(Se = 87.5%; Sp = 66.7%) infected animals could be recognized based on their serum protein 
profiles. 
Interestingly, preselecting protein peaks slightly increased the classification accuracy; using 
the 50 (day five post infection) or 100 (day 19 post infection) most significant differently 
expressed proteins resulted in the highest number of correctly classified animals. When the 
number of proteins was further limited to ten, a decrease in correctly classified animals was 
observed at day five (Se = 62.5%;Sp = 44.4%). However at day 19 post infection, profiles 
based on the ten most significant proteins could still identify 93% (= Se) of the infected 
animals, although only one of the seven non-infected animals was correctly classified 
(Sp = 14.3%) (Table 4). 
Two-group classification: PCV2/PPV versus control or PCV2/PRRSV versus 
control 
Serum protein profiles of PCV2/PPV infected animals were compared with profiles of non-
infected control animals on day five and day 19 using either data from a single time point or 
combining data from both days. Similarly, profiles of PCV2/PRRSV infected animals were 
compared with control animals. Results are summarized in Table 5. 
Table 5  Number of animals correctly classified according to infection status, evaluating 
two distinct classes 
Separate/ 
combined 
number 
of used 
protein 
markers
1
 
Day 5 
p.i. 
 Day 19 
p.i. 
 Day 5 
p.i. 
 Day 19 
p.i. 
 
PCV2/ 
PPV 
Control PCV2/ 
PPV 
Control PCV2/ 
PRRSV 
Control PCV2/ 
PRRSV 
Control 
Separate 10 2 (7) 5 (9) 4 (8) 5 (7) 8 (9) 6 (9) 5 (7) 6 (7) 
 20 2 3 5 5 8 6 5 6 
 50 2 5 6 5 6 6 5 6 
 100 2 5 6 3 7 7 5 6 
 200 1 5 6 3 8 8 4 6 
 500 1 5 6 2 8 7 5 5 
 586 1 5 6 2 8 7 5 5 
Combined 10 2 (7) 5 (9) 7 (8) 3 (7) 7 (9) 8 (9) 5 (7) 6 (7) 
 20 2 7 6 4 8 8 6 5 
 50 2 8 5 6 7 9 5 6 
 100 2 6 6 5 7 9 6 6 
 200 2 6 8 4 7 9 6 5 
 500 3 6 7 4 7 8 5 6 
 586 3 6 7 5 7 9 5 6 
The number of correctly classified animals according to infection status (2-way 
classification), based on serum protein profiles at day five and day 19 post infection (p.i.). 
The classification results are presented using either data of each day separately or combined. 
Protein components were selected based on their differential expression in piglets infected 
with PCV2/PPV, PCV2/PRRSV and control piglets, using those with the lowest p-values. In 
the top row, for each experimental group the total number of animals included in the analysis 
is specified between brackets. 
With regard to the classification of infected versus non-infected animals at day five post 
infection, results were poor for the PCV2/PPV group as only one of seven (Se = 14.3%; 
Sp = 55.6%) infected animals could be distinguished from control animals by profiles 
consisting of 586 protein components. The classification performance of serum protein 
profiles was much better for PCV2/PRRSV infected animals (Se = 88%; Sp = 77.8%) at day 
five post infection. 
As expected, overall results were better at day 19 post infection. Six of eight (Se = 75%; 
Sp = 28.6%) PCV2/PPV and five of seven (Se = 71.4%; Sp = 71.4%) PCV2/PRRSV infected 
animals could be distinguished from non-infected control animals by serum protein profiles 
using 586 protein components. This reflects the clinical signs, which were very similar for 
animals in both groups at 19 days post infection. 
Combining the data of both days slightly increased the classification accuracy as compared to 
profiles from either day five or day 19 post infection. This is especially true for the control 
groups as shown in Table 5 (Sp ranges from 66.7% - 100%). 
Again, using a preselection of the most significantly different protein peaks generally led to 
comparable or even better classification accuracy, similarly as described for the classification 
of infected versus non-infected animals. 
Three-group classification 
To assess the power of serum protein profiles as a diagnostic marker for specific infections, 
we explored the classification performance of serum protein profiles to distinguish between 
the three distinct animal groups (i) non-infected control animals, (ii) PCV2/PRRSV and (iii) 
PCV2/PPV infected animals) in one analysis, i.e. three-group classification. As expected, 
three-group classification as shown in Table 6 gave similar results compared to the two-group 
classification, but with lower classification accuracy. 
Table 6 Number of animals correctly classified according to infection status, evaluating 
three distinct classes 
  Day 5   Day 19  
number of protein  
components 
PCV2/PPV Control PCV2/PRRSV PCV2/PPV Control PCV2/PRRSV 
10 2 (7) 5 (9) 3 (9) 4 (8) 3 (7) 1 (7) 
20 4 6 5 6 3 3 
50 2 7 8 5 4 3 
100 1 7 6 5 4 3 
200 1 7 4 5 4 2 
500 2 6 6 5 3 2 
586 2 5 6 5 4 2 
The number of correctly classified animals according to disease status (3 way classification), 
based on serum protein profiles consisting of variable number of protein components. Serum 
protein profiles were obtained at day five and 19 post infection (p.i.) and data of both time 
points were combined for the statistical analysis. Protein components were selected based on 
their differential expression in piglets infected with PCV2/PPV, PCV2/PRRSV and control 
piglets, using those with the lowest p-values. In the top row, for each experimental group the 
total number of animals included in the analysis is specified between brackets. 
Table 7 shows the contingency tables for day five and 19 for true disease status and 
classification based on serum protein profiling using 50 most significant protein peaks. At 
day five, almost all (8/9) PCV2/PRRSV infected animals were classified correctly. A single 
PCV2/PRRSV infected animal was misclassified as PCV2/PPV infected. On the other hand, 
only two of seven PCV2/PPV animals were identified correctly. One was improperly 
classified as PCV2/PRRSV infected, while four animals could not be discriminated from 
non-infected animals. However at 19 days post infection, five of eight PCV2/PPV infected 
animals were accurately classified, while only three of seven PCV2/PRRSV infected animals 
could be identified based on their serum protein profiles. The other four animals were 
misclassified as PCV2/PPV infected. Control animals, when misclassified, were labeled as 
PCV2/PPV infected animals, but never as PCV2/PRRSV infected. 
Table 7  Contingency table showing the classification results according to infection 
status, evaluating three distinct classes 
  Day 5 p.i.1 Day 19 p.i.1 
  True status True status 
  PCV2/PP 
V 
Control PCV2/ 
PRRSV 
PCV2/ 
PPV 
Control PCV2/ 
PRRSV 
Classification 
results based 
on SELDITOF 
MS data 
PCV2/PPV 2 2 1 5 3 4 
Control 4 7 0 1 4 0 
PCV2/PRRSV 1 0 8 2 0 3 
1
 The p-value of the one-sided Fisher exact test was <0.001 and 0.095 at day 5 and 19 
respectively. 
Contingency table for 3-way classification, showing the number of correctly and incorrectly 
classified animals at day five and 19 post infection (p.i.), respectively. Classification was 
based on SELDI-TOF-MS serum protein profiles from piglets at day five and 19 after 
inoculation with either PCV2/PPV, PCV2/PRRSV or phosphate buffered saline (controls). 
Data of both time points were combined for the statistical analysis using 50 preselected 
protein components. Protein components were selected on their differential expression, using 
those with the lowest p-values. 
In conclusion, PCV2/PRRSV infected animals could well be distinguished from control 
animals as early as day five, while PCV2/PPV infections were best distinguished from non-
infected control animals at day 19. Classification results showed a very high significance at 
day five (P < 0.001) and were near significance at day 19 (P = 0.095). It can be concluded that 
based on SELDI-TOF protein profiles, at day five post infection PCV2/PRRSV infected 
animals are easier to distinguish compared to PCV2/PPV infected animals. 
Discussion 
Livestock health is an important issue for farmers and veterinarians as well as for consumers. 
It has an important economic drive as it affects productivity. In addition, from the animal 
welfare perspective there is a need for parameters that can objectively measure abnormalities 
or deterioration of health, preferably in an early stage of disease. Although the number of 
animals involved in this study was rather small, this study shows that SELDI-TOF MS 
profiles of high- and low-abundant serum proteins have potential as diagnostic markers for 
early detection of viral infections in pigs. We also show that classification of animals using 
ridge penalized partial least squares analysis of the protein profiles might be a powerful 
approach for this. 
We realize that in the current setting, we collected data under standardized experimental 
conditions. However, to make a useful and robust multi-marker test based on protein profiles, 
test development and validation should include the use of animals that originate from 
different breeds, different farms, different time points post infection and from animals with 
different disease history. Since such factors will create additional variation in protein profiles, 
larger sample sizes will be required. In this respect it is promising that combining profiles of 
day five and day 19 resulted in improved classification accuracies, suggesting that protein 
fingerprints of different time points after infection show similarities, which might be utilized 
under field conditions when time of infection varies. 
Correlation between SELDI-TOF MS results and clinical data 
The aim of this study was to explore the potential of quantitative data of high- and low-
abundant serum protein components as measured by SELDI-TOF-MS for early detection and 
diagnosis of viral infectious diseases in pigs. The experimental infection model (true status) 
of the animal groups was considered as the golden standard, which was reflected by 
representative clinical signs. The infection status was confirmed by PCR, after termination of 
the experiment. 
The SELDI-TOF MS serum protein fingerprints reflect the (pre-)clinical status of the two 
different disease courses having a comparable disease outcome. Among PCV2/PRRSV 
infected animals, body temperatures rose after day five post infection, while clinical scores 
increased sharply from day six onwards when infected animals were depressed and showed 
clear respiratory distress symptoms. Among PCV2/PPV infected animals body temperatures 
started to rise from day six onwards, while clinical scores did not increase until day seven 
post infection, typically consisting only of mild depression. It can be speculated that for 
PCV2/PPV infected animals protein fingerprints taken at day five may have been too early 
for diagnostic purposes, in contrast to the PRRSV/PCV2 infected animals. 
It should be noted that among the control animals no apparent clinical signs were observed. 
The low content of PCV2 viral DNA in tissue samples of some control animals are 
considered to have been “false positive” test results. However it cannot be fully excluded 
that, in spite of containment measures during the animal experiment, some level of cross 
contamination with the PCV2 virus occurred in the control group. 
Using a whole-protein profile approach instead of candidate proteins 
In the discovery of biomarkers a targeted approach is often used, aiming at a selection of 
predefined biomarkers based on current knowledge of the biological function of proteins or 
known associations. An example for such approach is the use of acute phase proteins for 
early diagnostic markers for infections. As levels of these proteins change early in the process 
of infection or tissue trauma, they have been suggested as suitable biomarkers [15,16]. 
In the present study, the analysis of acute phase proteins led to disappointing results 
(Figure 3). Similar to our experience, experiments conducted by Heegaard et al. found large 
between-animal variation and major differences in prechallenge concentrations between 
experimental groups [16], limiting the use of acute phase proteins as general disease markers. 
As an alternative, we explored a whole protein profile approach using SELDI-TOF-MS and 
comparative fingerprint analysis of whole protein profiles present in blood samples and 
studied its value for early disease diagnosis. This approach was chosen because it enables the 
identification and selection of “reactive profiles” without any prior knowledge of the 
biological functions of the components constituting the profiles. Although knowledge of 
biological function of proteins could have additional value and can be used as biological 
validation, it is not mandatory. Another advantage is that protein profile fingerprints enable 
the monitoring of quantitative changes rather than determining particular threshold levels of 
individual serum proteins. 
A major challenge in the discovery of protein biomarkers from blood is the vast difference in 
concentration between high- and low-abundant proteins. With traditional analysis methods, 
the high-abundance proteins usually dominate the proteome profiles, making the 
identification of less abundant protein components more challenging. Different strategies 
have been developed to eliminate some of the most abundant proteins from blood serum or 
plasma [17]. Here we applied the Proteominer™ fractionation kit from Bio-Rad. It is based 
on a bead-bound random peptide library that provides a vast amount of different binding sites 
for different proteins. Since there is only a small number of ligands that can bind to the same 
protein, this limits the number of identical high-abundant protein components that can bind to 
the bead-bound library. The combination of depletion, enrichment and fractionation through 
the Proteominer™ fractionation kit used in this study has led to the detection of a high 
number of differentially expressed high- and/or low-abundance proteins (as shown in 
Table 2) underlining the value of this technique. Focussing on low-abundance proteins, rather 
than the classical plasma proteins, might be a more promising approach since low abundant 
biomarkers may include proteins that either leak into the plasma from different tissues as a 
result of the infection or that play a role as signal molecules. 
Classification of infected versus non-infected animals 
The difficulty with multiple disease classification is that large sample sizes are required. 
Therefore, classifying animals as infected and not-infected or diseased and not-diseased is 
probably a first starting point. In this study, no disease symptoms were yet apparent at day 
five, except that a number of pigs in the PCV2/PRRSV group had elevated body 
temperatures. Notably, 14 of 16 (87.5%) infected animals could be recognized based on 
serum protein profiles. As expected, at day 19 post infection results were even better (93.3%). 
Further analysis will have to provide information whether these differences are due to 
inflammatory processes or other viral –host interactions. From experimental studies increases 
in IFNγ secreting cells and interleukin 10 have been shown as early as 7 and 10 days post 
infection, respectively [18–20]. 
Also classification according to distinct infection models showed promising results. 
However, the lower sensitivity as revealed by Table 6 suggests that classification with respect 
of specific infectious diseases will be challenging. Interestingly, the classification 
performance on both sample days for infected animals was superior compared to non-infected 
animals. This probably reflects the normal variation in serum protein profiles among 
“healthy” animals which is relatively large compared to infected animals in this small cohort. 
Also Batxelli-Molina et al. found more extensive variation in serum protein profiles from 
non-infected animals compared to infected animals [6]. 
It has been shown that in clinical settings multiple marker assays have increased sensitivity 
and specificity compared to single-marker assays [10]. It may be speculated that increasing 
the number of markers leads to a further improvement of the diagnostic performance. Indeed, 
the number of protein components that were statistically significant in differential expression 
between the distinct animal groups (as shown in Table 2) correlated well with the 
classification accuracy: the higher the number of significant protein markers between the 
groups, the better the classification accuracy. However, our findings also suggest that 
extending protein profiles to more than about 20 markers does not substantially increase 
classification accuracy. In our case, limiting the number of (preselecting) proteins from whole 
protein profiles of 586 to the ten most significant differentially expressed components did 
only marginally decrease the classification accuracy. Also the small number of animals used 
in this study limits the power of a high number of proteins in their contribution to 
classification accuracy. This indicates that although there might be quite a number of proteins 
markers associated with the disease status, performance of profiles seems to be more affected 
by the predictive value of individual proteins than by the number of proteins included in the 
profile. 
Statistical methods 
For evaluation of SELDI-TOF data a decision tree method is frequently used. However, to 
analyse complete sets of multiple protein peaks, more sophisticated statistical methods are 
required. We used ridge penalized partial least regression to classify animals, which is 
superior to decision tree analysis when there are many proteins contributing to the 
classification or, in other words, when many proteins are likely to be different between 
infected and non-infected animals. Partial least squares techniques have also been applied in 
disease classification in humans [2,21]. The significance testing of individual proteins was 
equivalent to the approach used by Batxelli-Molina et al. [6] and Barr et al. [5] for testing the 
significance of proteins in the diagnosis of prion diseases. 
In this case, we used one-leave-out cross-validation, because of the very limited number of 
animals per class. Due to the fact that one animal is left out, the unbalance in animals per 
disease class may be larger. Nevertheless, two-group as well as three-group classifications 
were quite successful, although with lower accuracy in the latter. Clearly larger sample sizes 
are necessary to improve the classification accuracy to more than 90% sensitivity and 
specificity required for diagnostic purposes. 
Towards development of biomarkers for livestock health 
This study shows the potential of protein profiles in combination with advanced statistical 
methods to distinguish infected from non-infected animals, providing etiological information 
as well. Such an approach may be valuable in the diagnosis of infectious diseases in the early 
stage of disease. In this study we examined sera from animals experimentally infected with 
PCV2 in combination with either PPV or PRRSV. As shown in Table 3, a number of protein 
components were significantly differentially expressed in multiple comparisons. For instance 
protein with mass:charge 8720 was evident in all four analyses. Such proteins may be 
regarded as key candidate markers and further investigation is warranted. 
In follow-up studies it would be of interest to explore the classification of animals according 
to aetiology, such as bacterial, viral, and parasitical infections. Also differentiation according 
to disease stage, i.e. acute versus chronic or affected organ system could be useful. The 
ultimate goal might be the development of assays for health versus disease as opposed to 
specific etiologic agents. 
The advances of proteomic technologies and promising study results have fed the hope to 
obtain biomarkers for improved and faster diagnostics. Due to the high costs and required 
technical skills, spectrometry has traditionally been limited to research settings. However, it 
is now increasingly used for diagnostic purposes in routine settings for the identification of 
infectious microorganisms [15]. SELDI-TOF-MS is a promising tool to determine protein 
profiles at medium throughput level and at reasonable costs. In human medicine, proteomic 
methods are increasingly used for early diagnosis of diseases [20]. In addition, it appears that 
the challenges of multiplexing such tests (e.g., on arrays) are sufficiently daunting that 
quantitative mass spectrometry may have value as an additional format for multiplexing 
protein measurements in the future given aggressive technology development. A major 
disadvantage for mass diagnostics as required in livestock veterinary medicine is the invasive 
procedure of blood sampling to get appropriate test material for analysis of biomarkers in 
serum. An alternative for the use of sera would be to explore the potential of protein profiles 
in easy to access biological samples like saliva, urine or faeces. Also, the recent 
developments in the field of micro- and nanotechnology have seen a rapid surge in interest in 
electronic devices for medical implants for in vivo health monitoring. In the human 
biomedical field several promising prototypes are emerging, for example for monitoring of 
patients with chronic cardiac or neurological diseases [22]. Similar developments may be 
expected for the veterinary health care sector. 
Conclusions 
In this study the potential of quantitative protein profiles by SELDI-TOF MS for early 
diagnosis of viral infections in pigs was explored. Results from serum of pigs experimentally 
infected with a combination of PCV/PPV and PCV2/PRRSV indicate that SELDI-TOF 
protein profiles have potential for detection of (viral) infection in pigs in early phase of the 
disease. The accuracy of classification of infected versus non-infected animals was good, as 
88% of the infected animals could be classified based on the serum protein profiles at day 
five post infection, that is before clinical symptoms became apparent. At day 19 post 
infection, 93% of the infected animals were classified as such. Results for PCV2/PRRSV 
were superior compared to PCV2/PPV infected animals, especially at day five post infection. 
The lower specificity, both at day five (67%) and day 19 post infection (57%), probably 
reflects the variation in serum protein profiles among non-infected animals. Limiting the 
number of proteins in the profile generally had minor effects on the classification accuracy. 
Accuracy of three-way classification was less than that of two-way classification. It can be 
concluded that SELDI-TOF MS protein profiles may have potential as biomarker for early 
diagnosis of viral infections in animal husbandry. 
Methods 
Experimental infection 
The animal experiment was according to Dutch law approved of by the Animal Ethical 
Committee of CVI (trial code 2008056c). Animals: Twenty- six, colostrum-deprived piglets 
from a conventional breeding line (TOPIGS 20™) of three weeks of age were housed in three 
different animal rooms with HEPA filtered supply and exhaust air filtration. Piglets were 
tested negative by PCR assay for PCV2, PPV and PRRSV prior to start of the study and 
allocated to three groups, which were either inoculated with PBS, or a combination with 
either PCV2/PRRSV or PCV2/PPV.Virus inocula: Tissue-culture propagated PCV2b strain 
1324 (2
nd
 passage), isolated in 2002 in the Republic of Ireland from a pooled tissue 
homogenate from a PMWS diseased animal and PPV strain 1005 (8
th
 passage) were kindly 
supplied by Prof. G. Allan, University of Belfast. The 7
th
 passage of PRRSV strain Ter-
Huurne, a EU-strain of PRRSV, propagated on lung macrophages was used. The titer of the 
PCV2 virus inoculum was 2x10
5
 TCID50/ml, of the PPV virus inoculum 2x10
6
 TCID50/ml 
and of the PRRSV virus inoculum 1x10
6
 TCID50/ml. On day zero, individual pigs received 
either the PBS sham inoculum, or the virus pools in a volume of three ml each. For this, 
aerosols of the inocula were produced by a commercial, gravity-fed, single trigger airbrush 
(Evolution™, Harder&Steenbeek, NL) with a nozzle of 0.2 mm, creating an aerosol with 
90% of droplets smaller than 99 μm in diameter, 50% of droplets smaller than 50 μm, and 
10% droplets smaller than 26 μm. The aerosol was administered intranasally alternately to 
each nostril during inspiration phases. Pigs were weighed weekly and followed clinically for 
a period of 27 days after infection. Rectal temperatures were measured twice daily. Inguinal 
lymph nodes were palpated daily to monitor increase in size and clinical symptoms were 
recorded by using pre-defined identifiers. These identifiers or a combination of identifiers 
were used to define a clinical score per day as no disease (0), mild (1), moderate (2) or severe 
(3) disease. Serum blood samples were taken from the external jugular vein at days 0, 2, 5, 7, 
9, 12, 15, 19 and 22. After coagulation, serum was separated by centrifugation at 2000 g for 
10 min. and stored at −80°C until analysis. At day 27, pigs were euthanized and a full 
necropsy was performed. Tissue specimens were taken for virus nucleic acid detection by 
polymerase chain reaction (PCR) analysis as described [14]. Briefly, RNA and DNA were 
extracted from organ suspensions using the QIAmp blood and tissue kit (Qiagen, Westburg, 
the Netherlands) for DNA and the High Pure RNA isolation kit for RNA (Roche diagnostics, 
Germany) according to the manufacturer‟s recommendations. To quantify the amount of 
PCV2 DNA copies in organ samples, a real-time fluorescent-probe PCR with the light-Cycler 
probes (LC red 640 – ATC TCA TCA TGT CCA CCG CCC AGG A) (FL fluorescein –CGT 
TGT ACT GTG GTA CGC TTG ACA GT) and the primers (1391; 5‟-CTC CCC TGT CAC 
CCT GGG TG -3‟ and 1577; 5‟-CTC TCC CGC ACC TTC GGA TAT-3‟) amplifying a 186-
bp fragment from the cap gene of PCV2 were used. The viral RNA concentration of PRRSV 
was assessed by a reverse transcription real time PCR with the following primers: 5‟-GAT 
GAC RTC CGG CAY C -3‟ (forward); 5‟- CAG TTC CTG CGC CTT GAT -3‟ (reverse) 
exerted on a MX3005 (Stratagene) machine. 
Acute phase proteins 
The serum concentration of haptoglobin was measured by use of an assay based on 
haemoglobin-haptoglobin binding [23] while serum CRP and pig MAP [24] and SAA 
concentrations were assayed by ELISA [16]. The concentration of Apo A1 was determined 
by radial immunodiffusion [16] and albumin was measured using a dye-binding assay for this 
protein on an automated biochemistry analyser (Prestige Analyser, Trio-Diagnostics Ltd, 
York). Assays for porcine APP were performed by ReactivLab Ltd, (Glasgow, UK). 
Serum enrichment and fractionation 
To detect the proteins present in low levels it is advisable to remove the most abundant 
proteins first [13]. Recently, a new method for enriching low-abundance proteins has been 
commercially available. This technology is known under de trade name of ProteoMiner® 
(BioRad, Veenendaal) and is based on the use of a combinatorial peptide binding library, 
which affinity-captures and amplifies the low abundance proteome [12]. ProteoMiner® 
treatment was performed according to manufacturer‟s recommendation. Briefly, 525 mg bulk 
beads swelled by rehydration with 10 ml 20% (v/v) aqueous EtOH. 100 μl of this beads 
solution is after washing with water and PBS in a 96-well filter plate (Pall-5039) mixed with 
200 μl centrifuged serum for two hours at 4°C. After binding and washing the beads three 
times with 200 μl PBS, the proteins were eluted three times with 20 μl of each of the four 
elution reagents; fraction1 (1 M NaCl, 20 mM HEPES pH7.5), fraction2 (200 mM glycine 
pH2.4), fraction3 (60% ethylene glycol), fraction4 (33% isopropyl alcohol, 16.7% 
acetonitrile, 0.1% TFA). Between every elution the beads where mixed for 5 minutes at room 
temperature, and centrifuged 1 min at 1000 g to collect the eluent from filter plate to a 
collection plate. 
Protein profiling 
Protein examination was performed according to the manufacturer‟s instructions. Briefly, a 
volume of 100 μl of the 10-fold diluted fractions, in appropriate binding buffer depending of 
the array, were incubated on the spots of three type of ProteinChip arrays (BioRad). A cation 
exchange (CM10) array with CM10 binding buffer (100 mM sodium-acetate pH 4.0), a 
copper-coated IMAC array with IMAC binding buffer (0.1 M sodium phosphate, 0.5 M NaCl 
pH7), and a reverse phase (H50) array with H50 binding buffer (10% acetonitrile, 0.1% 
trifluoroacetic acid (TFA)). 
After 60 minutes incubation the arrays were washed three times with 200 μl appropriate 
binding buffer, followed by a wash with 200 μlMilliQ water. 
After the arrays were dry, 2 × 1 μl of a saturated solution of sinapinic acid (SPA) in 50% 
acetonitrile (v/v), 0.5% trifluoroacetic acid (v/v) was added. The mass spectra of the proteins 
captured on the chips were recorded with the PCS4000 ProteinChip array reader (BioRad) by 
using ProteinChip Data Manager software 3.5.0. 
Previous to the measurements, the mass spectrometer was checked using the OQ kit (BioRad) 
for high voltage conditioning, detector calibration, detector sensitivity, mass drift, mass 
resolution, and mass accuracy. For calibrating, the All-in-One Protein Standard II (Biorad) 
was used. 
The resulting protein profiles, obtained from the time-of-flight mass spectrometry spectra 
were analysed for differences in expression using Bio-Rad ProteinChip Data Manager, 
version 3.5.0 with the integrated Biomarker Wizard
TM
 cluster analyses software (Biorad). 
First, peaks with a signal to noise ratio higher than five were selected. These were clustered 
with peaks having similar masses in other profiles with signal to noise ratios higher than two. 
Before cluster analyses, the baseline was subtracted and profiles were normalized using total 
ion current. 
Data processing 
After the identification of the peaks and normalization of the profiles, a total of 586 proteins 
from 26 animals were subjected to statistical analysis. For a number of proteins data were 
unavailable at some time points. Two animals died during the experiment and only data on 
day zero and day five were available. Additionally some missing values existed for subsets of 
proteins (e.g. CM10 or IMAC). Animals with absent data on a specific day were excluded 
only for that day. 
Significance testing proteins 
Initially an ANOVA was performed for each protein, to detect significant differences 
between disease groups (PCV2/PPV, PCV2/PRRSV, versus control, or infected versus 
uninfected animals) using an F-test. Multiple testing increases the risk of false positives. To 
reduce the risk of false positives, the false discovery rate (FDR) was used. The FDR was set 
to 5% and the obtained P-values of the F-test were converted into so-called q-values using the 
package „qvalue‟ in R [25]. The different comparisons are listed in Table 1. In addition, we 
tested also for differences prior to infection at day zero. No proteins showed significant 
differences between animal groups for any contrast, confirming that animals of the three 
experimental groups were very similar pre-infection. 
Classification of animals based on protein profiles 
For classification of animals based on expression of several proteins we used partial least 
squares with penalized logistic regression [26]. The method combines partial least squares 
with logistic regression. Partial least squares is both a tool for linear regression and a tool for 
dimension reduction [27] as we have more explanatory variables, i.e. proteins, than 
observations. Logistic regression is a common method for binary data using generalized 
linear models. The method used here combines both and makes it a suitable method for 
predicting to which categories animals belong based on many predictors [26]. Combining 
logistic regression with partial least squares has been also applied to disease classification in 
humans [28]. Here we used the functions rpls (for two-group classification) and mrpls (for 
three-group classification) from R-package plsgenomics [26]. The parameters lambda and the 
number of latent variables were determined using cross-validation. The ridge partial least 
squares method was applied in two ways: 1. by using all proteins and 2. by preselecting the 
top n proteins with the lowest p-values of ANOVA. 
To assess the accuracy of classification we performed a leave-one-out cross-validation, so 
that every record was left out once from the training set and was predicted based on the 
others being in the training set. When we used data of different days all records of one animal 
were used as validation set and the remaining as training set to prevent that the animal itself 
could have one record as training and another in the validation set. When using preselected 
proteins, the significance was based on the training set only to prevent the data from the 
validation animal effecting the preselection of proteins. 
Data from day five and day 19 were used both separately and combined for analyses 
concerning two-group classification (that is distinguishing either infected from non-infected 
animals, or animals from each disease group (PCV2/PPV, PCV2/PRRSV) versus control 
animals). For the three-group classification data of day five and 19 were combined. The 
accuracy of classification was given as number of correctly identified animals. In addition, 
sensitivity and specificity were calculated for two-way classifications, but not for three-way 
classifications because sensitivity and specificity are not suitable for that situation. All 
analyses are summarized in Table 1. 
Authors’ contributions 
MGJK coordinated the study, participated in its design and harmonized the drafting of the 
manuscript. HAM performed the statistical analyses and participated in the drafting of the 
manuscript. NSZ conceived of the animal experiment, provided the serum samples and 
participated in the drafting of the manuscript. LK performed the SELDI-TOF analyses and 
participated in the drafting of the manuscript. MAS conceived of the study, participated in its 
design and participated in the drafting of the manuscript. All authors read and approved the 
final manuscript. 
Acknowledgements 
This work was supported by the Dutch Ministry of Economic Affairs, Agriculture and 
Innovation (formerly Agriculture, Nature and Food Quality), through project “HiHealth”, 
KB-05-001-002 and by the European Union (6
th
 FP: 513928, PCVD). 
References 
1.  Elstner A, Stockhammer F, Nguyen-Dobinsky TN, Nguyen QL, Pilgermann I, Gill A, 
Guhr A, Zhang T, von Eckardstein K.Picht T et al: Identification of diagnostic serum 
protein profiles of glioblastoma patients.J Neurooncol 2010. 
2.  Gutkin M, Shamir R, Dror G: SlimPLS: a method for feature selection in gene 
expression-based disease classification.PLoS One 2009, 4(7):e6416. 
3.  Reddy G, Dalmasso EA: SELDI ProteinChip(R) Array Technology: Protein-Based 
Predictive Medicine and Drug Discovery Applications.J Biomed Biotechnol 2003, 
2003(4):237–241. 
4.  Rodriguez-Enriquez S,Pacheco-Velazquez SC, Gallardo-Perez JC, Marin-Hernandez A, 
Aguilar-Ponce JL, Ruiz-Garcia E, Ruizgodoy-Rivera LM, Meneses-Garcia A, Moreno-
Sanchez R: Multi-biomarker pattern for tumor identification and prognosis.J Cell 
Biochem, 2011. 
5.  Barr JB, Watson M, Head MW, Ironside JW, Harris N, Hogarth C, Fraser JR, Barron R: 
Differential protein profiling as a potential multi-marker approach for TSE 
diagnosis.BMC infectious diseases 2009, 9:188. 
6.  Batxelli-Molina I, Salvetat N, Andreoletti O, Guerrier L, Vicat G, Molina F, Mourton-
Gilles C: Ovine serum biomarkers of early and late phase scrapie.BMC veterinary 
research 2010, 6:49. 
7.  Rioux MC, Carmona C, Acosta D, Ward B, Ndao M, Gibbs BF, Bennett HP, Spithill TW: 
Discovery and validation of serum biomarkers expressed over the first twelve weeks of 
Fasciola hepatica infection in sheep.Int J Parasitol 2008, 38(1):123–136. 
8.  Zhong L, Taylor D, Begg DJ, Whittington RJ: Biomarker discovery for ovine 
paratuberculosis (Johne's disease) by proteomic serum profiling.Comp 
ImmunolMicrobiol Infect Dis 2011, 34(4):315–326. 
9.  Zhong L, Taylor DL, Whittington RJ: Proteomic profiling of ovine serum by SELDI-
TOF MS: optimisation, reproducibility and feasibility of biomarker discovery using 
routinely collected samples.Comp ImmunolMicrobiol Infect Dis 2010, 33(1):47–63. 
10.  Zhang Z, Bast RC Jr, Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang 
YY, Meng XY, et al: Three biomarkers identified from serum proteomic analysis for the 
detection of early stage ovarian cancer.Cancer Res 2004, 64(16):5882–5890. 
11.  Tang N, Tornatore P, Weinberger SR: Current developments in SELDI affinity 
technology.Mass spectrometry reviews 2004, 23(1):34–44. 
12.  Guerrier L, Righetti PG, Boschetti E: Reduction of dynamic protein concentration 
range of biological extracts for the discovery of low-abundance proteins by means of 
hexapeptide ligand library.Nat Protoc 2008, 3(5):883–890. 
13.  Marco-Ramell A, Bassols A: Enrichment of low-abundance proteins from bovine and 
porcine serum samples for proteomic studies.Res Vet Sci 2010, 89(3):340–343. 
14.  Wellenberg GJ, Stockhofe-Zurwieden N, Boersma WJ, De Jong MF, Elbers AR: The 
presence of co-infections in pigs with clinical signs of PMWS in The Netherlands: a 
case–control study.Res Vet Sci 2004, 77(2):177–184. 
15.  Gruys E, Toussaint MJ, Niewold TA, Koopmans SJ, van Dijk E, Meloen RH: 
Monitoring health by values of acute phase proteins.ActaHistochem 2006, 108(3):229–
232. 
16.  Heegaard PM, Stockmarr A, Pineiro M, Carpintero R, Lampreave F, Campbell FM, 
Eckersall PD, Toussaint MJ, Gruys E, Sorensen NS: Optimal combinations of acute phase 
proteins for detecting infectious disease in pigs.Vet Res 2011, 42(1):50. 
17.  Bandow JE: Comparison of protein enrichment strategies for proteome analysis of 
plasma.Proteomics 2010, 10(7):1416–1425. 
18.  Nevedomskaya E, Derks R, Deelder AM, Mayboroda OA, Palmblad M: Alignment of 
capillary electrophoresis-mass spectrometry datasets using accurate mass 
information.Analytical and bioanalytical chemistry 2009, 395(8):2527–2533. 
19.  Palmblad M, van der Burgt YE, Dalebout H, Derks RJ, Schoenmaker B, Deelder AM: 
Improving mass measurement accuracy in mass spectrometry based proteomics by 
combining open source tools for chromatographic alignment and internal 
calibration.Journal of proteomics 2009, 72(4):722–724. 
20.  Palmblad M, Tiss A, Cramer R: Mass spectrometry in clinical proteomics - from the 
present to the future.Proteomics Clinical applications 2009, 3(1):6–17. 
21.  Rajalahti T, Kroksveen AC, Arneberg R, Berven FS, Vedeler CA, Myhr KM, Kvalheim 
OM: A multivariate approach to reveal biomarker signatures for disease classification: 
application to mass spectral profiles of cerebrospinal fluid from patients with multiple 
sclerosis.J Proteome Res 2010, 9(7):3608–3620. 
22.  Yang G-Z, Yacoub M (eds.): Body Sensor Networks, 1st Edition edn; 2006. 
23.  Eckersall P, Duthie S, Safi S, Moffatt D, Horadagoda N, Doyle S, Parton R, Bennett D, 
Fitzpatrick J: An automated biochemical assay for haptoglobin: Prevention of 
interference from albumin.Comp Haem Inter 1999, 9:117–124. 
24.  Diack AB, Gladney CD, Mellencamp MA, Stear MJ, Eckersall PD: Characterisation of 
plasma acute phase protein concentrations in a high health boar herd.Vet 
ImmunolImmunopathol 2011, 139(2–4):107–112. 
25.  Storey JD, Tibshirani R: Statistical significance for genomewide 
studies.ProcNatlAcadSci U S A 2003, 100(16):9440–9445. 
26.  Fort G, Lambert-Lacroix S: Classification using partial least squares with penalized 
logistic regression.Bioinformatics 2005, 21(7):1104–1111. 
27.  Martens H, Naess T: Multivariate calibration. New York, US: Wiley; 1989. 
28.  Smit S, Hoefsloot HC, Smilde AK: Statistical data processing in clinical proteomics.J 
Chromatogr B AnalytTechnol Biomed Life Sci 2008, 866(1–2):77–88. 
 
 

Figure 2
Figure 3
